Published in Hum Mol Genet on January 29, 2010
FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med (2012) 1.85
Novel methylation markers of the dysexecutive-psychiatric phenotype in FMR1 premutation women. Neurology (2015) 1.45
Molecular Inconsistencies in a Fragile X Male with Early Onset Ataxia. Genes (Basel) (2016) 1.38
Emerging Roles for Long Non-Coding RNAs in Cancer and Neurological Disorders. Front Genet (2012) 1.13
Fragile X syndrome: the FMR1 CGG repeat distribution among world populations. Ann Hum Genet (2011) 1.08
FMR1 intron 1 methylation predicts FMRP expression in blood of female carriers of expanded FMR1 alleles. J Mol Diagn (2011) 0.94
FMR1 epigenetic silencing commonly occurs in undifferentiated fragile X-affected embryonic stem cells. Stem Cell Reports (2014) 0.92
The fragile x mental retardation syndrome 20 years after the FMR1 gene discovery: an expanding universe of knowledge. Clin Biochem Rev (2011) 0.91
Clinical and molecular implications of mosaicism in FMR1 full mutations. Front Genet (2014) 0.89
Modeling fragile X syndrome in the Fmr1 knockout mouse. Intractable Rare Dis Res (2014) 0.88
Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome. Clin Epigenetics (2016) 0.80
Neurological and endocrine phenotypes of fragile X carrier women. Clin Genet (2015) 0.80
Fear-specific amygdala function in children and adolescents on the fragile x spectrum: a dosage response of the FMR1 gene. Cereb Cortex (2012) 0.80
Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder. Curr Pharm Des (2015) 0.79
Methylation analysis of fragile X-related epigenetic elements may provide a suitable newborn screening test for fragile X syndrome. Genet Med (2010) 0.79
Mass spectrometry as a tool for studying autism spectrum disorder. J Mol Psychiatry (2013) 0.77
IVF for premature ovarian failure: first reported births using oocytes donated from a twin sister. Reprod Biol Endocrinol (2010) 0.77
Modeling diseases of noncoding unstable repeat expansions using mutant pluripotent stem cells. World J Stem Cells (2015) 0.77
Fragile X protein in newborn dried blood spots. BMC Med Genet (2014) 0.77
Advanced technologies for the molecular diagnosis of fragile X syndrome. Expert Rev Mol Diagn (2015) 0.75
Brain structure and intragenic DNA methylation are correlated, and predict executive dysfunction in fragile X premutation females. Transl Psychiatry (2016) 0.75
Detection of skewed X-chromosome inactivation in Fragile X syndrome and X chromosome aneuploidy using quantitative melt analysis. Expert Rev Mol Med (2015) 0.75
Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders. Genes (Basel) (2016) 0.75
Cascade Screening for Fragile X Syndrome/CGG Repeat Expansions in Children Attending Special Education in Sri Lanka. PLoS One (2015) 0.75
Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell (2007) 30.22
CpG islands in vertebrate genomes. J Mol Biol (1987) 23.16
Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell (1991) 17.00
Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res (1998) 14.63
Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A (2002) 12.33
Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell (1991) 12.27
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med (2006) 7.37
Absence of expression of the FMR-1 gene in fragile X syndrome. Cell (1991) 7.04
Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet (2000) 6.73
Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology (2001) 6.55
Fragile X genotype characterized by an unstable region of DNA. Science (1991) 4.33
DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet (1992) 4.22
Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain (2002) 4.05
Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet (2001) 3.82
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data. Am J Med Genet (1999) 3.82
A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn (2007) 3.80
Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex (2000) 3.43
Advances in the treatment of fragile X syndrome. Pediatrics (2009) 3.10
Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod (2004) 3.01
Genomic profiling of CpG methylation and allelic specificity using quantitative high-throughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res (2007) 2.80
Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet (2003) 2.71
Premature ovarian failure in the fragile X syndrome. Am J Med Genet (2000) 2.51
CG dinucleotide clustering is a species-specific property of the genome. Nucleic Acids Res (2007) 2.48
Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet (2000) 2.46
An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet (2007) 2.25
Understanding the molecular basis of fragile X syndrome. Hum Mol Genet (2000) 2.13
Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev (2004) 2.07
Molecular predictors of cognitive involvement in female carriers of fragile X syndrome. JAMA (1994) 2.01
Analysis of full fragile X mutations in fetal tissues and monozygotic twins indicate that abnormal methylation and somatic heterogeneity are established early in development. Am J Med Genet (1992) 1.70
High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet (1994) 1.68
Aging in individuals with the FMR1 mutation. Am J Ment Retard (2004) 1.68
FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet (2005) 1.67
Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod (2005) 1.64
Mental status of females with an FMR1 gene full mutation. Am J Hum Genet (1996) 1.57
A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One (2008) 1.57
Phenotype of V2-derived interneurons and their relationship to the axon guidance molecule EphA4 in the developing mouse spinal cord. Eur J Neurosci (2007) 1.52
Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine. Nucleic Acids Res (2002) 1.47
Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet (2004) 1.46
Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element. Hum Mol Genet (2004) 1.44
Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raised, and correlate with the number of CGG repeats. J Med Genet (2006) 1.42
Evidence for, and a spectrum of, neurological involvement in carriers of the fragile X pre-mutation: FXTAS and beyond. Clin Genet (2005) 1.37
Archived Guthrie blood spots as a novel source for quantitative DNA methylation analysis. Biotechniques (2008) 1.30
The bHLH transcription factor hand2 is essential for noradrenergic differentiation of sympathetic neurons. Development (2006) 1.25
Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am J Med Genet (1999) 1.25
Structural and functional characterization of the human FMR1 promoter reveals similarities with the hnRNP-A2 promoter region. Hum Mol Genet (1997) 1.20
Genotype-phenotype relationships in fragile X syndrome: a family study. Am J Hum Genet (1993) 1.18
The GATA2 transcription factor negatively regulates the proliferation of neuronal progenitors. Development (2006) 1.16
Interaction of the transcription factors USF1, USF2, and alpha -Pal/Nrf-1 with the FMR1 promoter. Implications for Fragile X mental retardation syndrome. J Biol Chem (2000) 1.16
An improved Diagnostic PCR Assay for identification of Cryptic Heterozygosity for CGG Triplet Repeat Alleles in the Fragile X Gene (FMR1). Mol Cytogenet (2008) 1.12
Small CGG repeat expansion alleles of FMR1 gene are associated with parkinsonism. Clin Genet (2009) 1.08
Methylation-specific multiplex ligation-dependent probe amplification enables a rapid and reliable distinction between male FMR1 premutation and full-mutation alleles. J Mol Diagn (2008) 1.05
Spastic paraparesis, cerebellar ataxia, and intention tremor: a severe variant of FXTAS? J Med Genet (2005) 0.98
X chromosome inactivation: theme and variations. Cytogenet Genome Res (2002) 0.95
Simplified molecular diagnosis of fragile X syndrome by fluorescent methylation-specific PCR and GeneScan analysis. Clin Chem (2006) 0.91
Fragile (X)(q27) sites in a pedigree with female carriers showing mild to severe mental retardation. J Med Genet (1982) 0.86
Methylation-dependent fragment separation: direct detection of DNA methylation by capillary electrophoresis of PCR products from bisulfite-converted genomic DNA. Anal Biochem (2006) 0.84
Molecular diagnosis of Fragile X syndrome. Expert Rev Mol Diagn (2009) 0.84
Polymerase chain reaction, nuclease digestion, and mass spectrometry based assay for the trinucleotide repeat status of the fragile X mental retardation 1 gene. Anal Chem (2009) 0.83
Improved methodology for assessment of mRNA levels in blood of patients with FMR1 related disorders. BMC Clin Pathol (2009) 0.83
Prenatal diagnosis of a hypermethylated full fragile X mutation in chorionic villi of a male fetus. J Med Genet (1993) 0.80
The CpG island of the FMR-1 gene is methylated differently among embryonic tissues: implication for prenatal diagnosis. Hum Reprod (1994) 0.78
Identification of small FRAXA premutations. Mol Diagn (2000) 0.77
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet (2003) 5.51
SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome Biol (2012) 4.99
Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA (2004) 4.88
Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol (2000) 4.27
The gene structure of human anti-haemophilic factor IX. EMBO J (1984) 4.09
Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice. Proc Natl Acad Sci U S A (2000) 3.53
Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol (2011) 3.51
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
A functional neo-centromere formed through activation of a latent human centromere and consisting of non-alpha-satellite DNA. Nat Genet (1997) 3.36
Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. Epidemiology (2011) 3.15
Training carers of stroke patients: randomised controlled trial. BMJ (2004) 2.95
Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A (2008) 2.91
Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr (2006) 2.73
The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet (2003) 2.73
Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord (2007) 2.68
Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature (1983) 2.59
Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol (2002) 2.58
Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev (2000) 2.53
Molecular cloning of the gene for human anti-haemophilic factor IX. Nature (1982) 2.50
Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J (2010) 2.43
Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet (2005) 2.35
Autism profiles of males with fragile X syndrome. Am J Ment Retard (2008) 2.35
Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol (2011) 2.29
An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet (2007) 2.25
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet (2005) 2.17
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Am J Clin Nutr (2012) 2.14
Characterisation and use of an intragenic polymorphic marker for detection of carriers of haemophilia B (factor IX deficiency). Lancet (1984) 2.08
Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA (2002) 2.06
Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X gene. Genome Res (2012) 2.04
Mitochondrial dysfunction in autism. JAMA (2010) 2.04
A functional marker centromere with no detectable alpha-satellite, satellite III, or CENP-B protein: activation of a latent centromere? Am J Hum Genet (1993) 2.03
The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr (2007) 2.02
Differences in stroke subtypes between black and white patients with stroke: the South London Ethnicity and Stroke Study. Circulation (2007) 2.01
A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry (2009) 1.98
The 10q25 neocentromere and its inactive progenitor have identical primary nucleotide sequence: further evidence for epigenetic modification. Genome Res (2000) 1.96
Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet (2010) 1.95
Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn (2009) 1.94
An enhanced polymerase chain reaction assay to detect pre- and full mutation alleles of the fragile X mental retardation 1 gene. J Mol Diagn (2005) 1.91
Digital imaging in pathology: whole-slide imaging and beyond. Annu Rev Pathol (2012) 1.89
Targeting and germ-line transmission of a null mutation at the metallothionein I and II loci in mouse. Proc Natl Acad Sci U S A (1993) 1.88
Targeted disruption of mouse centromere protein C gene leads to mitotic disarray and early embryo death. Proc Natl Acad Sci U S A (1998) 1.86
A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem (2010) 1.86
The (CGG)n repeat element within the 5' untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum Mol Genet (2003) 1.82
Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry (2006) 1.80
Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord (2007) 1.77
Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology (2008) 1.75
Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci (2006) 1.75
A novel chromatin immunoprecipitation and array (CIA) analysis identifies a 460-kb CENP-A-binding neocentromere DNA. Genome Res (2001) 1.75
Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial. Stroke (2003) 1.74
Centromere protein B null mice are mitotically and meiotically normal but have lower body and testis weights. J Cell Biol (1998) 1.68
Molecular characterization of de novo secondary trisomy 13. Am J Hum Genet (1994) 1.66
A 330 kb CENP-A binding domain and altered replication timing at a human neocentromere. EMBO J (2001) 1.65
Human centromeres and neocentromeres show identical distribution patterns of >20 functionally important kinetochore-associated proteins. Hum Mol Genet (2000) 1.63
Paternal transmission of fragile X syndrome. Am J Med Genet A (2004) 1.62
Genetics of the mammalian phenylalanine hydroxylase system. Studies of human liver phenylalanine hydroxylase subunit structure and of mutations in phenylketonuria. Biochem J (1979) 1.61
Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol Psychiatry (2011) 1.59
Defective chromosome segregation, microtubule bundling and nuclear bridging in inner centromere protein gene (Incenp)-disrupted mice. Hum Mol Genet (1999) 1.59
Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci Biobehav Rev (2006) 1.58
An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. J Mol Diagn (2010) 1.58
Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol (2010) 1.57
Neuropathic features in fragile X premutation carriers. Am J Med Genet A (2007) 1.56
Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep (2013) 1.56
Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Can Urol Assoc J (2010) 1.55
Evidence for age-related and individual-specific changes in DNA methylation profile of mononuclear cells during early immune development in humans. Epigenetics (2011) 1.55
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53
Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes. J Med Genet (2010) 1.50
Does an integrated care pathway improve processes of care in stroke rehabilitation? A randomized controlled trial. Age Ageing (2002) 1.50
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int (2009) 1.48
Mouse major (gamma) satellite DNA is highly conserved and organized into extremely long tandem arrays: implications for recombination between nonhomologous chromosomes. Genomics (1989) 1.47
Autistic spectrum disorder and the fragile X premutation. J Dev Behav Pediatr (2004) 1.47
Amygdala dysfunction in men with the fragile X premutation. Brain (2006) 1.46
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
Sequence analysis of an 80 kb human neocentromere. Hum Mol Genet (1999) 1.45
HZwint-1, a novel human kinetochore component that interacts with HZW10. J Cell Sci (2000) 1.44
Training care givers of stroke patients: economic evaluation. BMJ (2004) 1.44
Redistribution of transcription start sites within the FMR1 promoter region with expansion of the downstream CGG-repeat element. Hum Mol Genet (2004) 1.44
The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43
Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest (2012) 1.42
Transcript levels of the intermediate size or grey zone fragile X mental retardation 1 alleles are raised, and correlate with the number of CGG repeats. J Med Genet (2006) 1.42
Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice. J Clin Invest (2011) 1.39
Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol (2011) 1.39
Evidence for widespread changes in promoter methylation profile in human placenta in response to increasing gestational age and environmental/stochastic factors. BMC Genomics (2011) 1.39
A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia (2004) 1.38
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab (2008) 1.37
Longitudinal, genome-scale analysis of DNA methylation in twins from birth to 18 months of age reveals rapid epigenetic change in early life and pair-specific effects of discordance. Genome Biol (2013) 1.36
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis (2005) 1.34
A quantitative ELISA assay for the fragile x mental retardation 1 protein. J Mol Diagn (2009) 1.33
AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet Med (2012) 1.33
Copy number variation in patients with disorders of sex development due to 46,XY gonadal dysgenesis. PLoS One (2011) 1.32
Obesity and hyperleptinemia in metallothionein (-I and -II) null mice. Proc Natl Acad Sci U S A (1998) 1.32
Increased number of sex chromosomes affects height in a nonlinear fashion: a study of 305 patients with sex chromosome aneuploidy. Am J Med Genet A (2010) 1.31
Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes. J Biol Chem (1995) 1.31
A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. J Neurodev Disord (2009) 1.31